Patients with diabetic macular edema and moderately severe to severe nonproliferative diabetic retinopathy, as determined on the ETDRS Diabetic Retinopathy Severity Scale, greatly benefit from intravitreal anti-VEGF injection with ranibizumab, with more robust results than in patients with less or more severe diabetic retinopathy, according to a study.
“If untreated, these patients have a substantial risk of progressing to PDR,” Charles C. Wykoff, MD, told Ocular Surgery News.
The study was a post hoc analysis of the phase 3 RIDE and RISE clinical trials, in which the safety and
Uncategorized